Date: 2016-03-15
Type of information: Services contract
Compound:
Company: Txcell (France) PCT, a Caladrius Company (USA - CA)
Therapeutic area: Technology - Services
Type agreement: services contrat manufacturing production
Action mechanism:
Disease:
Details: * On March 15, 2016, TxCell announced the appointment of PCT, a Caladrius Company, as its contract manufacturing organization (CMO) in the US. The initial relationship could transition to a technology transfer, and to PCT having responsibility for the future manufacturing of TxCell’s clinical supply in the US.
PCT, a subsidiary of Caladrius Biosciences is a leading development and manufacturing partner to the cell therapy industry. PCT has been set up to overcome fundamental challenges of its clients’ cell therapy manufacturing with a wide range of services, from process development to GMP manufacturing and logistics. Initially, PCT will operate a preliminary strategic evaluation of the existing TxCell manufacturing processes. These processes were designed by TxCell for its first platform of antigen specific regulatory T cells products (the ASTrIA platform). Following completion, TxCell could start transferring its technology to PCT. This will achieve a source of clinical supply in the US for use when required.
Financial terms:
Latest news:
